MYELOPEROXIDASE EXPRESSION IN ACUTE LYMPHOBLASTIC LEUKEMIA - A RARE CASE REPORT

*Ashim Manta, Nitu Mani Khakhlari, Gayatri Gogoi and Projnan Saikia
Department of Pathology, Assam Medical College, Dibrugarh
*Author for Correspondence

ABSTRACT
Expression of myeloperoxidase (MPO) is considered diagnostic in acute myeloid leukemias (AML). Whereas the expression of MPO in lymphoblastic leukemia is very unusual. Herein we report a case of MPO positive, in otherwise typical acute lymphoblastic leukemia (ALL) without the expression of other myeloid markers. Complete haemogram showed anaemia with leukocytosis. Peripheral blood smear revealed fair numbers of blasts with thrombocytopenia. Cytochemistry was negative for MPO. Immunophenotyping revealed positivity for CD10, HLA DR, CD19, CD79a, CD20, and MPO. Impression: B-cell ALL with MPO positivity. The study primarily shows that MPO expression in childhood acute leukemia revealing typical lymphoblastic morphology does rarely exist.

Keywords: Myeloperoxidase (MPO), Acute Lymphoblastic Leukemia (ALL)

INTRODUCTION
Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, accounting for approximately 30% of all childhood malignancies (Wintrobe’s, 12th edition). It is a neoplastic disorder that is rapidly fatal if untreated. The diagnosis and lineage assignment of acute leukemias follow the criteria of the French-American British (FAB) Cooperative Group and rely on morphology and cytochemical analysis. The presence of greater than 3% myeloperoxidase (MPO) positive leukemic blasts by light microscopy is considered as the diagnostic criteria for acute myeloid leukemia (Kantarjian et al., 1990).
Recent studies have demonstrated lineage fidelity (myeloid or lymphoid) is not preserved in many cases of acute leukemia. Lineage heterogeneity has been pursued through morphological, cytogenetic, immunophenotyping and molecular studies (Kantarjian et al., 1990).
Here we present a case of acute lymphoblastic leukaemia which showed MPO as the only myeloid marker positive in the blasts population detected by flowcytometry.

CASES
The patient was a 14 year old female who presented in the paediatrics out patient department with the symptoms of headache, fever, bleeding gums and abdominal distension for 2 weeks. Blood sample for complete haemogram and peripheral blood smear examination were studied. Subsequently cytochemistry and immunophenotyping were done.
Clinically patient had pallor and hepatosplenomegaly Routine blood examination revealed anaemia and marked leukocytosis. Differential count showed 75% of blasts.
Peripheral blood examination smear revealed severe microcytic hypochromic anaemia, moderate anisocytosis and microspherocytes. There was marked leukocytosis with fair number of blasts and thrombocytopenia. Two populations of blasts were seen with predominance of small blasts showing scanty cytoplasm and inconspicuous nucleoli while another population of blasts had abundant cytoplasm showing one to two nucleoli.
Morphological diagnosis: ALL L2 (figure 1 & 2)
Cytochemistry was negative for Myeloperoxidase (MPO).
Immunophenotyping was done in BD FACS Canto II machine. Sample was prepared by Stain-lyse-wash method, number of events acquired were 10,000; number of events gated were 7485 (74.9%) on SSC/CD45 plot; around 12% of the blasts population showed MPO positivity with dim intensity. No
Case Report

Other myeloid markers were positive. Immunophenotyping revealed positivity for CD19, CD79a, C10, CD20, HLA DR, TdT & MPO.

Impression: B-cell ALL with dim MPO expression.

Figure 1: PBS 100x view showing blasts

Figure 2: CD19 positive

Figure 3: CD79a positive

Figure 4: CD10 positive

Figure 5: CD20 positive

Figure 6: HLA DR positive
DISCUSSION
We studied a total of 102 cases of Acute Leukemia, of which 32 cases were ALL and MPO with dim expression as single myeloid marker was found in only one case. Cytochemistry was negative for MPO. However, immunophenotyping revealed ~12% of the cells with Myeloperoxidase positivity. All the other markers of myeloid/monocytic lineage were negative. The cells were typically of the B-cell ALL type with strong positivity for B lymphoid markers.

Rytting et al., (2009) studied 5 cases of adult ALL that demonstrate typical ALL immunophenotypes without myeloid surface markers but show strong (>20%) MPO activity by enzymatic (functional) and immunologic (flow cytometric) methods.

Tauchi et al., (1991) studied a case of ALL that expressed CD10, CD19, CD20, HLA-DR, Cytochemistry was negative for MPO, but ultrastructural study demonstrated some of the cytoplasmic granules with MPO positivity.

Serrano et al., (1997) described two cases of acute leukemia in which blast cells had lymphoid morphology, ultrastructure, immunophenotype and molecular rearrangements, but expressed significant levels of MPO gene (MPO mRNA) by reverse transcriptase polymerase chain reaction (RT-PCR), in the absence of translation to protein.

Kantarjian et al., (1990) reported seven adult patients with untreated acute lymphocytic leukemia (ALL) who manifested 5% to 40% myeloperoxidase (MPO)-positive blasts by electron microscopy (EM).

Conclusion
Myeloperoxidase (MPO) is an enzyme found primarily in the granules of myeloid cells. MPO positivity has been considered the hallmark that distinguishes ALL from acute myeloid leukemia, despite the numerous surface markers that are currently used to characterize leukemias. However, several recent reports indicated that ALL cells also may exhibit MPO mRNA and even MPO protein. So this suggests there can be expression of lineage-specific genes in acute leukemia cells with diverse phenotypic characteristics. The presented case is a B cell ALL showing strong positivity for all the B lymphoid markers but significant percentage of the blasts showing MPO (dim expression) as the positive myeloid marker. This might add a dilemma whether to categorize it as Mixed phenotypic acute leukemia. We analysed the findings according to scoring system of European group for the immunological classification of leukemias (EGIL) and the scoring is less than 2. So it can be concluded that it is a case of B cell ALL with coexpression of a myeloid marker i.e. MPO.

REFERENCES
Case Report


